NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02813967,S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer,https://clinicaltrials.gov/study/NCT02813967,,COMPLETED,"This was a randomised, multicenter, phase 3 trial. Patients who were age of 70 years or older with histologically confirmed esophageal cancer were randomly assigned to S-1 concurrent with radiotherapy or radiotherapy alone.The primary endpoint was overall survival.",NO,Esophageal Cancer|Chemoradiation,RADIATION: Radiotherapy 54 Gy|RADIATION: Radiotherapy 60 Gy|DRUG: S-1,"Overall survival, 2-year over survival, 5 years","Progression-free survival, 5 years|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, 5 years","the quality of life, assessed with the European Organisation for Research and Treatment of Cancer quality-of-life core questionnaire QLQ-C30, 5 years|the oesophagus-specific quality-of-life, assessed with the European Organisation for Research and Treatment of Cancer quality-of-life the oesophagus-specific questionnaire QLQ-OES18, 5 years",Zhejiang Cancer Hospital,,ALL,OLDER_ADULT,PHASE3,298,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,ZJCH-E-E,2016-06,2020-08,2020-08,2016-06-27,,2020-09-16,"Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China",
